Development and validation of a clinical scoring system for predicting risk of HCC in asymptomatic individuals seropositive for anti-HCV antibodies.
about
Molecular prognostic prediction in liver cirrhosisAPASL consensus statements and recommendations for hepatitis C prevention, epidemiology, and laboratory testing.Personalized management of hepatocellular carcinoma based on molecular information: future prospects.Dynamic prediction of risk of liver-related outcomes in chronic hepatitis C using routinely collected data.The Hepatitis Viral Status in Patients With Hepatocellular Carcinoma: a Study of 3843 Patients From Taiwan Liver Cancer NetworkGenetics Variants and Serum Levels of MHC Class I Chain-related A in Predicting Hepatocellular Carcinoma Development in Chronic Hepatitis C Patients Post Antiviral Treatment.Tailored algorithms for hepatocellular carcinoma surveillance: Is one-size-fits-all strategy outdated?Hepatitis C viral infection increases the risk of lymphoid-neoplasms: A population-based cohort study.Diabetes, hepatocellular carcinoma, and mortality in hepatitis C-infected patients: A population-based cohort study.Nomogram for individualized prediction of hepatocellular carcinoma occurrence in hepatitis C virus cirrhosis (ANRS CO12 CirVir).Circulating Osteopontin and Prediction of Hepatocellular Carcinoma Development in a Large European Population.Risk factors and prevention of hepatocellular carcinoma in the era of precision medicine.Predicting Hepatitis B Virus (HBV) Surface Antigen Seroclearance in HBV e Antigen-Negative Patients With Chronic Hepatitis B: External Validation of a Scoring System.
P2860
Q26784251-AF815FC7-5D17-420A-85BF-4FCE8F11091DQ30250088-E3F5954A-483B-4F59-B141-83F65D6CEA17Q35881575-0A93CA3A-BE29-43C3-AE23-1490C3F2AE35Q35928072-56BFDEDE-9C61-4F19-B5CE-4D99598A8D06Q36822340-4274EDD4-5D8A-4A00-BA86-CF8C04851A9FQ37584311-C4FE8CD6-BCF8-427E-9648-A341F2199B9CQ39197775-F51D0523-5B4D-4216-97F9-796C7914D6A5Q40216845-811BB72B-12C3-42C0-B113-00115368DC0AQ40418302-5CF40B7B-98B1-4F4C-9B11-A4C9E0F77C0FQ40680346-30A6A330-10D4-47B0-A8C5-6C9DD5F99FC4Q40684396-C1623767-5488-4D3D-8F86-14EF36FDD628Q41921861-548B21DF-63A4-4526-95B7-51E323E11065Q42180497-6D458BEE-53CA-42A5-93CD-3FCF4BA1F47C
P2860
Development and validation of a clinical scoring system for predicting risk of HCC in asymptomatic individuals seropositive for anti-HCV antibodies.
description
2014 nî lūn-bûn
@nan
2014 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Development and validation of ...... itive for anti-HCV antibodies.
@ast
Development and validation of ...... itive for anti-HCV antibodies.
@en
Development and validation of ...... itive for anti-HCV antibodies.
@nl
type
label
Development and validation of ...... itive for anti-HCV antibodies.
@ast
Development and validation of ...... itive for anti-HCV antibodies.
@en
Development and validation of ...... itive for anti-HCV antibodies.
@nl
prefLabel
Development and validation of ...... itive for anti-HCV antibodies.
@ast
Development and validation of ...... itive for anti-HCV antibodies.
@en
Development and validation of ...... itive for anti-HCV antibodies.
@nl
P2093
P2860
P1433
P1476
Development and validation of ...... itive for anti-HCV antibodies.
@en
P2093
Chien-Jen Chen
Chin-Lan Jen
Gilbert L'Italien
Hwai-I Yang
Li-Yu Wang
Mei-Hsuan Lee
R.E.V.E.A.L.-HCV Study Group
Sheng-Nan Lu
P2860
P304
P356
10.1371/JOURNAL.PONE.0094760
P407
P50
P577
2014-05-06T00:00:00Z